Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Derick Moody

Clinical Nurse Specialist, Psychiatric/Mental Health Springville, UT Physician Assistant

NPI 1235551409 CMS profile 10810384

672 W 400 S Ste 201, Springville, UT 84663

Open in the dashboard

General payments

$8,306

451 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Derick Moody of Springville, UT is reported in the CMS Open Payments database as having received $8,306 across 451 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Clinical Nurse Specialist, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,069 105
2024 General $1,908 96
2023 General $1,672 95
2022 General $1,598 93
2021 General $1,059 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Derick Moody
  • Clinical Nurse Specialist, Psychiatric/Mental Health median
  • Middle half of Clinical Nurse Specialist, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Derick Moody were reported at $2,069. Among 300 Clinical Nurse Specialist, Psychiatric/Mental Health profiles paid that year, the median was $245 and the middle half received between $78 and $929.

Show as a table
Year Derick Moody Clinical Nurse Specialist, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,059 $153 $44–$540 $132
2022 $1,598 $207 $60–$748 $149
2023 $1,672 $197 $55–$898 $160
2024 $1,908 $189 $49–$804 $164
2025 $2,069 $245 $78–$929 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,063 79 payments
  2. Janssen Pharmaceuticals, Inc $993 38 payments
  3. Teva Pharmaceuticals USA, Inc. $837 57 payments
  4. ITI, Inc. $785 34 payments
  5. Otsuka America Pharmaceutical, Inc. $775 52 payments
  6. Neurocrine Biosciences, Inc. $644 28 payments
  7. Alkermes, Inc. $486 23 payments
  8. Lundbeck LLC $404 23 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $361 20 payments
  10. Axsome Therapeutics, Inc. $336 15 payments
  11. Other $1,623 82 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,306 451 payments
Products named General payments · program years 2021–2025
  1. SPRAVATO $803 27 payments
  2. VRAYLAR $778 61 payments
  3. REXULTI Psychiatry $615 38 payments
  4. INGREZZA $577 25 payments
  5. Austedo XR $551 30 payments
  6. CAPLYTA $498 24 payments
  7. ABILIFY MAINTENA $445 37 payments
  8. REXULTI Psychiatry $389 22 payments
  9. LYBALVI $361 21 payments
  10. TRINTELLIX $361 20 payments
  11. Other $4,890 271 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 39 drugs

Part D claims

1,245

Median for Physician Assistant: 241

Drug cost

$68,434

Median for Physician Assistant: $4,110

Branded share of claims

23.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 13 $17,444
Trintellix Vortioxetine Hydrobromide Brand 16 $9,234
Belsomra Suvorexant Brand 17 $7,556
Vyvanse Lisdexamfetamine Dimesylate Brand 13 $4,984
Lurasidone Hcl Generic 43 $3,560
Lisdexamfetamine Dimesylate Generic 17 $2,761
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 42 $2,293
Quetiapine Fumarate Generic 115 $1,783
Asenapine Maleate Generic 14 $1,581
Gabapentin Generic 53 $1,454

The 10 drugs with the highest cost, of 39 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$6,310

Medicare's payments for the services billed

Medicare patients

25

Average age 62

Services billed

136

14 women, 11 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 52%
Cancer 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SPRAVATO
  • Janssen Pharmaceuticals, Inc $382
$382 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $207
$207 — —
REXULTI
  • Lundbeck LLC $100
  • Otsuka America Pharmaceutical, Inc. $92
$192 — —
VRAYLAR
  • AbbVie, Inc. $186
$186 13 —
CAPLYTA
  • ITI, Inc. $155
$155 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

451 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Psychiatric/Mental Health in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record